US healthcare company Organon (NYSE:OGN) announced on Thursday that it has entered into a commercialisation agreement with Daiichi Sankyo Europe to distribute and promote Nilemdo in France, Denmark, Iceland, Sweden, Finland, and Norway.

This agreement expands Organon's cardiovascular portfolio and targets patients with dyslipidemia who are unable to achieve adequate cholesterol control with statins.

Nilemdo, a first-in-class lipid-lowering therapy containing bempedoic acid, offers an alternative for patients who are statin-intolerant or for whom statins are contraindicated. The collaboration addresses a gap in cardiovascular care, particularly for women, who face a significantly higher risk of statin intolerance than men.

Under the agreement, Daiichi Sankyo Europe will remain the marketing authorisation holder, while Organon will act as the local representative in the covered markets.

Nilemdo was approved by the European Medicines Agency in February 2020 and is the only treatment in its class currently available in these countries.